Ontology highlight
ABSTRACT: Purpose
Genome editing holds both tremendous therapeutic promise and significant potential risk. Sickle cell disease (SCD), the most commonly inherited blood disorder, is a frontline candidate for the clinical applications of this tool. However, there is limited knowledge of patient community values and concerns regarding this new technology. This study aims to investigate the perspectives of three key decision-makers (patients, parents, and physicians) toward participation in future CRISPR-mediated somatic genome editing clinical trials.Methods
We utilized a mixed-methods approach, involving an educational video tool, two-part survey, and 15 moderated, audio-recorded focus groups, which were conducted in seven U.S. cities.Results
Study participants expressed hope t
SUBMITTER: Persaud A
PROVIDER: S-EPMC6606394 | biostudies-literature | 2019 Aug
REPOSITORIES: biostudies-literature